Atrium Therapeutics, Inc.
RNAHealthcare|Biotechnology|US
$8.34
+0.02 (+0.24%)
Tangible Book / Share
$12.54
Cash / Share
$15.45
Financials
Financial Snapshot
Market Cap
$142.7M
Enterprise Value
$71.7M
Revenue (TTM)
$23.5M
Net Income (TTM)
-$93.2M
Cash & Investments
$264.2M
Net Cash
$262.5M
Free Cash Flow (TTM)
—
Operating CF (TTM)
—
Debt/Equity
0.01
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2025 | TTM |
|---|---|---|---|
| Cash & Investments | $270.0M | $264.2M | |
| Operating Cash Flow | -$41.1M | — | |
| Free Cash Flow | -$42.6M | — | |
| Capital Expenditure | -$1.4M | — | |
| Financing Cash Flow | $42.6M | — |
R&D Spending
R&D (TTM)
$50.5M
R&D Intensity
214.9%
R&D Growth vs Prior
-6.1%
| Metric | Trend | 2025 | TTM |
|---|---|---|---|
| Revenue | $18.6M | $23.5M | |
| R&D Expense | $53.8M | $50.5M | |
| R&D % of Revenue | 288.7% | 214.9% | |
| SG&A | $41.7M | $60.4M |
Income Statement
| Metric | Trend | 2025 | TTM |
|---|---|---|---|
| Revenue | $18.6M | $23.5M | |
| Cost of Revenue | $0.00 | $494.0K | |
| Gross Profit | $18.6M | $23.0M | |
| R&D | $53.8M | $50.5M | |
| SG&A | $41.7M | $60.4M | |
| Operating Income | -$76.8M | -$96.4M | |
| Interest Expense | $0.00 | $0.00 | |
| Pretax Income | -$76.8M | -$93.3M | |
| Net Income | -$76.7M | -$93.2M | |
| EPS (Diluted) | -4.48 | -3.85 | |
| EBITDA | -$76.5M | -$95.1M | |
| Shares Out. (M) | 17.11 | 17.11 |
Balance Sheet
| Metric | Trend | 2025 | TTM |
|---|---|---|---|
| Cash & Equivalents | $270.0M | $72.6M | |
| Short-Term Investments | $0.00 | $191.6M | |
| Total Current Assets | $272.8M | $275.1M | |
| Total Assets | $278.4M | $280.5M | |
| Total Current Liabilities | $41.8M | $31.5M | |
| Long-Term Debt | $0.00 | $0.00 | |
| Total Liabilities | $71.1M | $65.9M | |
| Stockholders' Equity | $207.3M | $214.6M | |
| Retained Earnings | $0.00 | -$8.1M |
Cash Flow Statement
| Metric | Trend | 2025 | TTM |
|---|---|---|---|
| Operating Cash Flow | -$41.1M | — | |
| Capital Expenditure | -$1.4M | — | |
| Free Cash Flow | -$42.6M | — | |
| Investing Cash Flow | -$1.4M | — | |
| Financing Cash Flow | $42.6M | — | |
| Issuance of Stock | $0.00 | — | |
| Repurchase of Stock | $0.00 | — | |
| Net Debt Issuance | $0.00 | — | |
| Stock Based Comp. | $7.7M | — | |
| Net Change in Cash | $0.00 | — |
Dilution Tracker
Shares Outstanding
17M
5-Year Share Growth
+0.0%
Stock Issuance (TTM)
—
| Metric | Trend | 2025 | TTM |
|---|---|---|---|
| Shares Out. (M) | 17.11 | 17.11 | |
| Change vs Prior % | — | -0.0% | |
| Stock Issuance | $0.00 | — | |
| Stock Repurchase | $0.00 | — | |
| Stock Based Comp. | $7.7M | — |
Margins & Profitability
| Metric | Trend | 2025 | TTM |
|---|---|---|---|
| Gross Margin % | 100.0% | 97.9% | |
| Operating Margin % | -412.6% | -410.2% | |
| Net Margin % | -411.9% | -396.5% | |
| EBITDA Margin % | -410.9% | -404.6% | |
| FCF Margin % | -228.7% | — | |
| ROE % | -37.0% | -42.9% | |
| ROA % | -27.5% | -33.2% | |
| ROIC % | -31.9% | -38.4% | |
| R&D / Revenue % | 288.7% | 214.9% |
Valuation
P/E (TTM)At Loss
P/S6.07
P/B0.66
EV/EBITDAAt Loss
EV/Revenue3.05
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$12.54
Net Current Assets / Share
$12.22
Graham Net-Net
$11.59
Cash / Share
$15.45
| Metric | Trend | 2025 | TTM |
|---|---|---|---|
| P/E Ratio | -3.29 | -2.17 | |
| P/S Ratio | 13.56 | 6.07 | |
| P/B Ratio | 1.22 | 0.66 | |
| EV/EBITDA | 0.18 | -0.75 | |
| EV/Revenue | -0.75 | 3.05 |
Analyst Estimates & Quality
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $35.0M | $2.7M | $4.0M |
| Net Income | -$75.9M | -$130.7M | -$105.7M |
| EPS | $-4.30 | $-6.45 | $-6.18 |
| # Analysts (EPS) | 3 | 3 | 2 |